Phenominer Database Results (309 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
SS/Jr absolute change in systolic blood pressure controlled sodium content diet (2 %) (between 34 and 38 days) then controlled exposure to darkness then controlled exposure to ambient light Joe B, et al., J Hypertens 2003 Nov;21(11):2077-84. arterial blood pressure trait male 73.0 days-80.0 days 8 22.6 mmHg 1.05 2.97 intra-aortic abdominal radiotelemetry 10 diurnal difference 65497 611
SS.LEW-(D1Rat211-D1Rat18)/Mco absolute change in systolic blood pressure controlled sodium content diet (2 %) (between 34 and 38 days) then controlled exposure to darkness then controlled exposure to ambient light Joe B, et al., J Hypertens 2003 Nov;21(11):2077-84. arterial blood pressure trait male 73.0 days-80.0 days 8 14.4 mmHg 1.63 4.61 intra-aortic abdominal radiotelemetry 10 diurnal difference 65502 611
SHRSP/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 188.1 mmHg 5.9 10.22 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65659 613
SHRSP.WKY-(D2Rat13-D2Rat157)/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 139.0 mmHg 8.1 14.03 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65679 613
SHRSP.WKY-(D2Rat13-D2Rat157)/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 130.8 mmHg 4.8 8.31 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65685 613
SHRSP.WKY-(D2Rat13-D2Mit5)/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 127.9 mmHg 4.0 6.93 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65693 613
WKY.SHRSP-(Fst-Pklr)/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 91.9 mmHg 7.4 12.82 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65717 613
SR/Jr diastolic blood pressure controlled sodium content diet (8 %) (between 62 and 69 days) then controlled exposure to darkness St. Lezin EM, et al., J Clin Invest 1996 Jan 15;97(2):522-7 arterial blood pressure trait female 56.0 days-63.0 days 8 serial mean 89.0 mmHg 1.0 2.83 intra-aortic abdominal radiotelemetry 604800.0 5 s every 5 min nightly for a week 11701 119
WKY/NCrl diastolic blood pressure controlled sodium content diet (8 %) (for 14 days) then controlled exposure to darkness (for 12 hours) Iwai N, et al., Circulation 1999 Nov 2;100(18):1923-9. arterial blood pressure trait male 126.0 days 7 93.9 mmHg 1.29 3.4 vascular indwelling catheter method left common carotid artery 0.0 nighttime (7 PM - 7 AM) 70088 1281
WKY.SHR-(D1Mgh14-D1Rat77)/Iwai systolic blood pressure controlled sodium content diet (8 %) (for 14 days) then controlled exposure to darkness (for 12 hours) Iwai N, et al., Circulation 1999 Nov 2;100(18):1923-9. arterial blood pressure trait male 126.0 days 8 136.2 mmHg 1.03 2.9 vascular indwelling catheter method left common carotid artery 0.0 nighttime (7 PM - 7 AM) 70094 1281
SS/JrHsdMcwi diastolic blood pressure controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days) then controlled exposure to darkness (for 12 hours) Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. arterial blood pressure trait female 89.0 days-91.0 days 15 serial mean 139.0 mmHg 6.0 23.24 vascular indwelling catheter method left femoral artery 0.0 69446 151
WKY/Izm systolic blood pressure controlled exposure to darkness Xiao B, et al., J Hypertens. 2010 Nov 8. arterial blood pressure trait male 94.0 days serial mean 120.0 mmHg 17.0 radiotelemetry 0.0 avg of 5 measurements for 84614 990
RCS/N ERG oscillatory potential lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013. eye electrophysiology trait not specified 60.0 days 3 67.6 uV 16.69 28.9 electroretinography cornea 0.0 lens puncture 30 days scotopic ocillatory index ERG 108568 3124
Hsd:SD scotopic B wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 4 456.0 uV electroretinography cornea 0.0 scotopic b-wave ERG 108641 3128
Hsd:SD scotopic A wave amplitude of ERG waveform vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 4 142.0 uV electroretinography cornea 0.0 subretinal injection 30 days scotopic a-wave ERG 108642 3128
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 34.0 days 8 13.0 uV 13.0 36.77 electroretinography 0.0 untreated control electrical activity measurement of retina (CMO:0003653)/A wave 108374 3121
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 34.0 days 8 45.0 uV 42.0 118.79 electroretinography 0.0 untreated control b-wave amplitude ERG 108377 3121
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 62.0 days 5 11.0 uV 12.0 26.83 electroretinography cornea 0.0 subretinal injection 42 days adenovirus a-wave amplitude ERG 108388 3121
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 15.03 uV 4.72 11.56 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108393 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 25.3 uV 2.85 6.98 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108399 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 109.52 uV 22.74 55.7 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108400 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 161.92 uV 30.48 74.66 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108401 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 190.68 uV 32.08 78.58 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108402 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 162.07 uV 9.02 22.09 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108419 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 240.67 uV 14.84 36.35 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108421 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 7.62 uV 1.56 3.82 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108422 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 149.83 uV 9.83 24.08 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108425 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 202.33 uV 17.65 43.23 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108426 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 621.67 uV 35.23 86.3 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108439 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 26.68 uV 7.67 18.79 electroretinography cornea 0.0 subretinal injection 30 min pbs a-wave amplitude ERG 108447 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 440.0 uV 43.67 106.97 electroretinography cornea 0.0 subretinal injection 30 min CHPG b-wave amplitude ERG 108454 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 579.0 uV 50.99 124.9 electroretinography cornea 0.0 subretinal injection 30 min CHPG b-wave amplitude ERG 108457 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 358.5 uV 35.71 87.47 electroretinography cornea 0.0 subretinal injection 30 min pbs b-wave amplitude ERG 108459 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 598.67 uV 39.64 97.1 electroretinography cornea 0.0 subretinal injection 30 min pbs b-wave amplitude ERG 108463 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 144.39 uV 13.24 43.91 electroretinography cornea 0.0 subretinal injection 2 days pbs a-wave amplitude ERG 108473 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 201.55 uV 19.9 66.0 electroretinography cornea 0.0 subretinal injection 2 days pbs a-wave amplitude ERG 108475 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 44.02 uV 13.47 44.67 electroretinography cornea 0.0 subretinal injection 2 days CHPG b-wave amplitude ERG 108476 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 56.72 uV 16.42 54.46 electroretinography cornea 0.0 subretinal injection 2 days pbs b wave amplitude ERG 108482 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 334.55 uV 43.36 143.81 electroretinography cornea 0.0 subretinal injection 2 days CHPG b-wave amplitude ERG 108478 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 605.83 uV 62.69 153.56 electroretinography cornea 0.0 subretinal injection 10 days CHPG b-wave amplitude ERG 108505 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 429.5 uV 66.11 161.94 electroretinography cornea 0.0 subretinal injection 10 days CHPG b-wave amplitude ERG 108502 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 393.0 uV 65.49 160.42 electroretinography cornea 0.0 subretinal injection 10 days pbs b wave amplitude ERG 108507 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 16.12 uV 3.84 9.41 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP a-wave amplitude ERG 108512 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 584.5 uV 55.51 135.97 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP b-wave amplitude ERG 108525 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 644.33 uV 50.52 123.75 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP b-wave amplitude ERG 108526 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 119.08 uV 22.02 53.94 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP b-wave amplitude ERG 108524 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 748.17 uV 64.77 158.65 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP b-wave amplitude ERG 108528 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 354.0 uV 16.81 41.18 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs b-wave amplitude ERG 108531 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 47.53 uV 9.4 23.03 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs b-wave amplitude ERG 108530 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 53.0 days 5 96.3 uV 10.3 23.03 electroretinography cornea 0.0 plasmid delivery 37 days pVAX2-rGDNF scotopic a-wave ERG 108725 3131
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) and sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 70.0 days 3 23.8 uV 1.9 3.29 electroretinography cornea 0.0 plasmid delivery 54 days pVAX2 scotopic a-wave ERG 108746 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) and sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 70.0 days 3 231.0 uV 5.0 8.66 electroretinography cornea 0.0 plasmid delivery 54 days pVAX2 scotopic b-wave ERG 108749 3131
RCS/N scotopic B wave amplitude of ERG waveform gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.01 cd x s/m2) Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. rod electrophysiology trait not specified 242.0 days 4 223.0 uV 28.0 56.0 electroretinography cornea 0.0 AAV8 injection 240 days treated eye scotopic b-wave amplitude ERG 108684 3129
RCS/LavRrrc scotopic B wave amplitude of ERG waveform vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 35.0 days 4 95.22 uV 16.19 32.38 electroretinography retina 0.0 pbs vehicle injection 14 days 109856 3157
RCS/LavRrrc scotopic B wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 49.0 days 4 13.93 uV 1.49 2.98 electroretinography retina 0.0 untreated control 28 days 109858 3157
RCS/N scotopic B wave amplitude of ERG waveform gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. rod electrophysiology trait not specified 62.0 days 6 500.0 uV 61.24 150.0 electroretinography cornea 0.0 AAV8 injection 60 days treated eye scotopic b-wave amplitude ERG 108682 3129
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 53.0 days 5 475.0 uV 41.0 91.68 electroretinography cornea 0.0 plasmid delivery 37 days pVAX2-rGDNF scotopic b-wave ERG 108727 3131
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 75.0 days 5 23.1 uV 4.0 8.94 electroretinography cornea 0.0 plasmid delivery 59 days scotopic a-wave ERG 108730 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 75.0 days 5 135.0 uV 38.0 84.97 electroretinography cornea 0.0 plasmid delivery 59 days pVAX2-rGDNF scotopic b-wave ERG 108731 3131
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 5.86 uV 0.76 2.01 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108536 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 3.13 uV 1.81 4.79 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108548 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 10.28 uV 1.69 4.47 electroretinography cornea 0.0 subretinal injection 4 days pbs b-wave amplitude ERG 108554 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 32.75 uV 13.42 35.51 electroretinography cornea 0.0 subretinal injection 4 days pbs b-wave amplitude ERG 108555 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 94.13 uV 15.33 40.56 electroretinography cornea 0.0 subretinal injection 4 days pbs b-wave amplitude ERG 108556 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 159.83 uV 21.35 56.49 electroretinography cornea 0.0 subretinal injection 4 days pbs b-wave amplitude ERG 108558 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 179.49 uV 20.75 54.9 electroretinography cornea 0.0 subretinal injection 4 days pbs b-wave amplitude ERG 108559 3123
RCS/LavRrrc scotopic B wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 35.0 days 4 61.63 uV 15.09 30.17 electroretinography retina 0.0 untreated control 14 days 109855 3157
SHRSP/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 185.5 mmHg 4.5 7.79 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65653 613
SHRSP/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 167.2 mmHg 5.2 9.01 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65655 613
SHRSP/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 134.6 mmHg 3.5 6.06 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65657 613
WKY/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 4 continuous mean 104.4 mmHg 6.9 13.8 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65667 613
WKY/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 4 continuous mean 117.7 mmHg 7.5 15.0 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65671 613
WKY/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 112.2 mmHg 2.7 4.68 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65673 613
SHRSP.WKY-(D2Rat13-D2Rat157)/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 161.6 mmHg 5.4 9.35 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65677 613
SHRSP.WKY-(D2Rat13-D2Rat157)/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 115.4 mmHg 4.4 7.62 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65681 613
SHRSP.WKY-(D2Rat13-D2Mit5)/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 176.8 mmHg 6.3 10.91 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65689 613
SHRSP.WKY-(D2Rat13-D2Mit5)/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 156.8 mmHg 11.8 20.44 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65691 613
WKY.SHRSP-(Fst-Pklr)/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 108.4 mmHg 1.4 2.42 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65715 613
WKY.SHRSP-(Fst-Pklr)/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 124.3 mmHg 1.6 2.77 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65719 613
BN/NHsdMcwi absolute change in mean arterial blood pressure controlled sodium content diet (0.4 %) (for 28 days) then controlled sodium content diet (8 %) (for 30 days) then controlled exposure to ambient light (for 12 hours) then controlled exposure to darkness (for 12 hours) Cowley AW Jr, et al., Physiol Genomics 2000 Apr 27;2(3):107-15. arterial blood pressure trait male 91.0 days-93.0 days 42 continuous mean 4.5 mmHg 2.0 12.96 vascular indwelling catheter method femoral artery 0.0 left femoral artery increase 64928 229
SR/Jr diastolic blood pressure controlled sodium content diet (8 %) (between 48 and 55 days) then controlled exposure to darkness St. Lezin EM, et al., J Clin Invest 1996 Jan 15;97(2):522-7 arterial blood pressure trait male 70.0 days-77.0 days 7 serial mean 105.0 mmHg 4.0 10.58 intra-aortic abdominal radiotelemetry 604800.0 5 s every 5 min nightly for a week 11697 119
WKY/NCrl systolic blood pressure controlled sodium content diet (8 %) (for 14 days) then controlled exposure to darkness (for 12 hours) Iwai N, et al., Circulation 1999 Nov 2;100(18):1923-9. arterial blood pressure trait male 126.0 days 7 131.7 mmHg 0.83 2.2 vascular indwelling catheter method left common carotid artery 0.0 nighttime (7 PM - 7 AM) 70086 1281
WKY.SHR-(D1Mgh14-D1Rat77)/Iwai systolic blood pressure controlled exposure to darkness (for 12 hours) Iwai N, et al., Circulation 1999 Nov 2;100(18):1923-9. arterial blood pressure trait male 112.0 days 8 132.8 mmHg 0.46 1.3 vascular indwelling catheter method left common carotid artery 0.0 nighttime (7 PM - 7 AM) 70090 1281
WKY.SHR-(D1Mgh14-D1Rat77)/Iwai diastolic blood pressure controlled exposure to darkness (for 12 hours) Iwai N, et al., Circulation 1999 Nov 2;100(18):1923-9. arterial blood pressure trait male 112.0 days 8 94.6 mmHg 0.99 2.8 vascular indwelling catheter method left common carotid artery 0.0 nighttime (7 PM - 7 AM) 70092 1281
BN/NHsdMcwi mean arterial blood pressure controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days) then controlled exposure to darkness (for 12 hours) Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. arterial blood pressure trait female 89.0 days-91.0 days 20 serial mean 111.0 mmHg 2.7 12.07 vascular indwelling catheter method left femoral artery 0.0 69447 151
WKY.SHRSP-(D1Rat171-D1Wox33)/Izm systolic blood pressure controlled exposure to darkness Xiao B, et al., J Hypertens. 2010 Nov 8. arterial blood pressure trait male 94.0 days serial mean 121.0 mmHg 5.0 radiotelemetry 0.0 avg of 5 measurements for 84615 990
SHRSP/Izm systolic blood pressure controlled exposure to darkness Xiao B, et al., J Hypertens. 2010 Nov 8. arterial blood pressure trait male 94.0 days serial mean 226.0 mmHg 30.0 radiotelemetry 0.0 avg of 5 measurements for 84618 990
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 87.0 days 5 24.5 uV 4.9 10.96 electroretinography cornea 0.0 plasmid delivery 71 days scotopic a-wave ERG 108734 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 87.0 days 5 83.0 uV 7.0 15.65 electroretinography cornea 0.0 plasmid delivery 71 days pVAX2-rGDNF scotopic b-wave ERG 108735 3131
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 48.0 days 5 17.0 uV 5.0 11.18 electroretinography 0.0 untreated control a-wave amplitude ERG 108380 3121
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 62.0 days 5 13.0 uV 17.0 38.01 electroretinography 0.0 untreated control b-wave amplitude ERG 108389 3121
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 108.63 uV 17.19 42.11 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108395 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 143.17 uV 20.27 49.65 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108397 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 11.22 uV 1.07 2.62 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108416 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 594.5 uV 24.04 58.89 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108433 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 201.67 uV 18.19 44.56 electroretinography cornea 0.0 subretinal injection 30 min CHPG a-wave amplitude ERG 108444 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 190.83 uV 21.76 53.3 electroretinography cornea 0.0 subretinal injection 30 min pbs a-wave amplitude ERG 108450 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 218.83 uV 22.09 54.11 electroretinography cornea 0.0 subretinal injection 30 min pbs a-wave amplitude ERG 108451 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 49.97 uV 12.07 29.57 electroretinography cornea 0.0 subretinal injection 30 min pbs b-wave amplitude ERG 108458 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 118.51 uV 12.59 41.76 electroretinography cornea 0.0 subretinal injection 2 days CHPG a-wave amplitude ERG 108468 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 71.37 uV 8.23 27.3 electroretinography cornea 0.0 subretinal injection 2 days CHPG a-wave amplitude ERG 108466 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 104.17 uV 12.63 41.89 electroretinography cornea 0.0 subretinal injection 2 days CHPG a-wave amplitude ERG 108467 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 351.91 uV 47.74 158.34 electroretinography cornea 0.0 subretinal injection 2 days CHPG b-wave amplitude ERG 108479 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 170.91 uV 16.52 54.79 electroretinography cornea 0.0 subretinal injection 2 days pbs a-wave amplitude ERG 108474 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 389.91 uV 52.11 172.83 electroretinography cornea 0.0 subretinal injection 2 days CHPG b-wave amplitude ERG 108480 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 410.45 uV 48.4 160.52 electroretinography cornea 0.0 subretinal injection 2 days pbs b wave amplitude ERG 108483 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 24.73 uV 6.11 14.97 electroretinography cornea 0.0 subretinal injection 10 days CHPG a-wave amplitude ERG 108489 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 188.33 uV 15.56 38.11 electroretinography cornea 0.0 subretinal injection 10 days CHPG a-wave amplitude ERG 108493 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 13.98 uV 3.06 7.5 electroretinography cornea 0.0 subretinal injection 10 days pbs a wave amplitude ERG 108494 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 100.23 uV 12.78 31.3 electroretinography cornea 0.0 subretinal injection 10 days pbs a wave amplitude ERG 108496 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 145.83 uV 14.32 35.08 electroretinography cornea 0.0 subretinal injection 10 days pbs a wave amplitude ERG 108497 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 206.0 uV 11.62 28.46 electroretinography cornea 0.0 subretinal injection 10 days pbs a wave amplitude ERG 108499 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 533.17 uV 67.99 166.54 electroretinography cornea 0.0 subretinal injection 10 days pbs b wave amplitude ERG 108508 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 19.36 uV 3.48 8.52 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP a-wave amplitude ERG 108513 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 241.17 uV 16.89 41.37 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP a-wave amplitude ERG 108517 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 89.88 uV 11.06 27.09 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs a-wave amplitude ERG 108521 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 16.11 uV 3.41 8.35 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs a-wave amplitude ERG 108519 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 382.33 uV 22.98 56.29 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs b-wave amplitude ERG 108532 3123
RCS/N scotopic A wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. rod electrophysiology trait not specified 62.0 days 6 16.0 uV 6.94 17.0 electroretinography cornea 0.0 AAV8 injection 60 days contralateral control eye scotopic a-wave amplitude ERG 108681 3129
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 53.0 days 5 352.0 uV 26.0 58.14 electroretinography cornea 0.0 plasmid delivery 37 days scotopic b-wave ERG 108701 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 75.0 days 5 114.0 uV 16.1 36.0 electroretinography cornea 0.0 plasmid delivery 59 days scotopic b-wave ERG 108703 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 53.0 days 5 186.0 uV 23.8 53.22 electroretinography cornea 0.0 37 days control for age matched plasmid injection scotopic b-wave ERG 108702 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 75.0 days 5 24.7 uV 13.8 30.86 electroretinography cornea 0.0 59 days control for age matched plasmid injection scotopic b-wave ERG 108704 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 70.0 days 3 199.0 uV 17.0 29.44 electroretinography cornea 0.0 plasmid delivery 54 days pVAX2-rGDNF scotopic b-wave ERG 108750 3131
RCS/N scotopic A wave amplitude of ERG waveform gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (21.6 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. rod electrophysiology trait not specified 62.0 days 6 175.0 uV 14.7 36.0 electroretinography cornea 0.0 AAV8 injection 60 days treated eye scotopic a-wave amplitude ERG 108680 3129
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 48.0 days 5 110.0 uV 40.0 89.44 electroretinography cornea 0.0 subretinal injection 28 days adenovirus b-wave amplitude ERG 108385 3121
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 48.0 days 5 27.0 uV 22.0 49.19 electroretinography cornea 0.0 subretinal injection 28 days adenovirus a-wave amplitude ERG 108382 3121
RCS/N scotopic B wave amplitude of ERG waveform lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013. rod electrophysiology trait not specified 60.0 days 3 30.5 uV 7.51 13.0 electroretinography cornea 0.0 lens puncture 30 days scotopic b-wave ERG 108567 3124
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 18.53 uV 4.77 12.63 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108538 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 27.22 uV 4.74 12.54 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108539 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 19.05 uV 3.75 9.92 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108550 3123
RCS/LavRrrc scotopic B wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 77.0 days 4 12.57 uV 1.42 2.84 electroretinography retina 0.0 untreated control 56 days 109861 3157
WKY/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 138.9 mmHg 2.6 4.5 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65665 613
SHRSP.WKY-(D2Rat13-D2Rat157)/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 191.2 mmHg 3.4 5.89 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65675 613
WKY.SHRSP-(D2Mit5-D2Mgh12)/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 149.3 mmHg 7.0 12.12 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65701 613
WKY.SHRSP-(Fst-Pklr)/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 104.8 mmHg 7.5 12.99 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65721 613
SS.SR-(D13Mit9-D13Mit1)/Jr systolic blood pressure controlled sodium content diet (8 %) (between 48 and 55 days) then controlled exposure to darkness St. Lezin EM, et al., J Clin Invest 1996 Jan 15;97(2):522-7 arterial blood pressure trait male 70.0 days-77.0 days 8 serial mean 136.0 mmHg 1.0 2.83 intra-aortic abdominal radiotelemetry 604800.0 5 s every 5 min nightly for a week 11703 119
SR/Jr systolic blood pressure controlled sodium content diet (8 %) (between 62 and 69 days) then controlled exposure to darkness St. Lezin EM, et al., J Clin Invest 1996 Jan 15;97(2):522-7 arterial blood pressure trait female 56.0 days-63.0 days 8 serial mean 128.0 mmHg 2.0 5.66 intra-aortic abdominal radiotelemetry 604800.0 5 s every 5 min nightly for a week 11699 119
SS.SR-(D13Mit9-D13Mit1)/Jr diastolic blood pressure controlled sodium content diet (8 %) (between 48 and 55 days) then controlled exposure to darkness St. Lezin EM, et al., J Clin Invest 1996 Jan 15;97(2):522-7 arterial blood pressure trait male 70.0 days-77.0 days 8 serial mean 102.0 mmHg 1.0 2.83 intra-aortic abdominal radiotelemetry 604800.0 5 s every 5 min nightly for a week 11705 119
SS/JrHsdMcwi mean arterial blood pressure controlled sodium content diet (0.1 %) (for 28 days) then controlled sodium content diet (8 %) (for 30 days) and controlled exposure to darkness (for 12 hours) Cowley AW Jr, et al., Physiol Genomics 2000 Apr 27;2(3):107-15. arterial blood pressure trait male 91.0 days-93.0 days 35 continuous mean 172.0 mmHg 7.0 41.41 vascular indwelling catheter method femoral artery 14400.0 left femoral artery 12005 229
WKY/NCrl diastolic blood pressure controlled exposure to darkness (for 12 hours) Iwai N, et al., Circulation 1999 Nov 2;100(18):1923-9. arterial blood pressure trait male 112.0 days 7 92.5 mmHg 1.59 4.2 vascular indwelling catheter method left common carotid artery 0.0 nighttime (7 PM - 7 AM) 70084 1281
SS/JrHsdMcwi systolic blood pressure controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days) then controlled exposure to darkness (for 12 hours) Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. arterial blood pressure trait female 89.0 days-91.0 days 15 serial mean 184.0 mmHg 7.7 29.82 vascular indwelling catheter method left femoral artery 0.0 69444 151
BN/NHsdMcwi heart rate controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days) then controlled exposure to darkness (for 12 hours) Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. heart pumping trait female 89.0 days-91.0 days 18 serial mean 386.0 beats/min 4.1 17.39 vascular indwelling catheter method left femoral artery 0.0 69449 151
SHRSP.WKY-(D1Smu13-D1Wox33)/Izm systolic blood pressure controlled exposure to darkness Xiao B, et al., J Hypertens. 2010 Nov 8. arterial blood pressure trait male 94.0 days serial mean 219.0 mmHg 22.0 radiotelemetry 0.0 avg of 5 measurements for 84619 990
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 48.0 days 5 51.0 uV 33.0 73.79 electroretinography cornea 0.0 subretinal injection 28 days adenovirus b-wave amplitude ERG 108384 3121
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 9.73 uV 2.39 5.85 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108398 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 371.67 uV 28.82 70.59 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108406 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 411.83 uV 43.52 106.6 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108408 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 460.67 uV 47.48 116.3 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108411 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 592.83 uV 68.9 168.77 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108413 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 373.83 uV 17.47 42.79 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108429 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 437.0 uV 33.32 81.62 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108431 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 399.83 uV 37.74 92.44 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108436 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 356.17 uV 23.35 57.2 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108435 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 6.38 uV 1.4 3.43 electroretinography cornea 0.0 subretinal injection 30 min CHPG a-wave amplitude ERG 108440 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 78.77 uV 13.41 32.85 electroretinography cornea 0.0 subretinal injection 30 min pbs a-wave amplitude ERG 108448 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 146.78 uV 16.49 40.39 electroretinography cornea 0.0 subretinal injection 30 min pbs a-wave amplitude ERG 108449 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 514.67 uV 47.85 117.21 electroretinography cornea 0.0 subretinal injection 30 min CHPG b-wave amplitude ERG 108455 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 587.83 uV 53.2 130.31 electroretinography cornea 0.0 subretinal injection 30 min CHPG b-wave amplitude ERG 108456 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 438.83 uV 24.27 59.45 electroretinography cornea 0.0 subretinal injection 30 min pbs b-wave amplitude ERG 108460 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 12.43 uV 2.29 7.6 electroretinography cornea 0.0 subretinal injection 2 days pbs a-wave amplitude ERG 108470 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 87.05 uV 8.87 29.42 electroretinography cornea 0.0 subretinal injection 2 days pbs a-wave amplitude ERG 108472 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 410.09 uV 45.37 150.48 electroretinography cornea 0.0 subretinal injection 2 days CHPG b-wave amplitude ERG 108481 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 119.33 uV 19.43 47.59 electroretinography cornea 0.0 subretinal injection 10 days CHPG a-wave amplitude ERG 108491 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 166.85 uV 19.57 47.94 electroretinography cornea 0.0 subretinal injection 10 days CHPG a-wave amplitude ERG 108492 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 587.17 uV 49.54 121.35 electroretinography cornea 0.0 subretinal injection 10 days pbs b wave amplitude ERG 108509 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 570.67 uV 53.5 131.05 electroretinography cornea 0.0 subretinal injection 10 days pbs b wave amplitude ERG 108510 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 138.93 uV 9.28 22.73 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs a-wave amplitude ERG 108523 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 419.0 uV 21.83 53.47 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs b-wave amplitude ERG 108533 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 11.45 uV 3.56 9.42 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108537 3123
RCS/LavRrrc b-wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. eye electrophysiology trait both  days 5 24.0 uV 10.0 22.36 electroretinography cornea 0.0 scotopic b-wave ERG 108665 3128
RCS/N scotopic B wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd x s/m2) Deng WT, et al., Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904. doi: 10.1167/iovs.11-8831. rod electrophysiology trait not specified 62.0 days 6 61.0 uV 19.6 48.0 electroretinography cornea 0.0 AAV8 injection 60 days contralateral control eye scotopic b-wave amplitude ERG 108683 3129
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 53.0 days 5 60.2 uV 8.5 19.01 electroretinography cornea 0.0 plasmid delivery 37 days scotopic a-wave ERG 108726 3131
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 70.0 days 3 26.7 uV 2.7 4.68 electroretinography cornea 0.0 plasmid delivery 54 days pVAX2-rGDNF scotopic a-wave ERG 108747 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 70.0 days 3 144.0 uV 29.0 50.23 electroretinography cornea 0.0 plasmid delivery 54 days pVAX2-rGDNF scotopic b-wave ERG 108751 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 34.0 days 8 39.0 uV 23.0 65.05 electroretinography cornea 0.0 subretinal injection 14 days adenovirus b-wave amplitude ERG 108378 3121
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 34.0 days 8 79.0 uV 43.0 121.62 electroretinography cornea 0.0 subretinal injection 14 days adenovirus b-wave amplitude ERG 108379 3121
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 62.0 days 5 9.7 uV 9.9 22.14 electroretinography cornea 0.0 subretinal injection 42 days adenovirus a-wave amplitude ERG 108387 3121
Hsd:SD scotopic B wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 9 488.0 uV electroretinography cornea 0.0 scotopic b-wave ERG 108647 3128
RCS/LavRrrc scotopic B wave amplitude of ERG waveform human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 49.0 days 4 204.9 uV 52.13 104.26 electroretinography retina 0.0 hPDLSC transplant 28 days 109857 3157
RCS/LavRrrc scotopic B wave amplitude of ERG waveform vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 49.0 days 4 29.44 uV 7.44 14.87 electroretinography retina 0.0 pbs vehicle injection 28 days 109859 3157
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 112.85 uV 11.14 27.29 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP a-wave amplitude ERG 108514 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 455.17 uV 35.54 87.05 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs b-wave amplitude ERG 108535 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 145.24 uV 12.56 33.23 electroretinography cornea 0.0 subretinal injection 4 days pbs a wave amplitude ERG 108544 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 31.96 uV 9.73 25.74 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108553 3123
RCS/LavRrrc scotopic B wave amplitude of ERG waveform human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 77.0 days 4 45.89 uV 3.23 6.45 electroretinography retina 0.0 hPDLSC transplant 56 days 109860 3157
WKY/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 4 continuous mean 144.2 mmHg 8.8 17.6 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65663 613
WKY/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 98.8 mmHg 2.8 4.85 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65669 613
SHRSP/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 156.4 mmHg 6.5 11.26 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65683 613
SHRSP.WKY-(D2Rat13-D2Mit5)/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 221.3 mmHg 15.4 26.67 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65687 613
SHRSP.WKY-(D2Rat13-D2Mit5)/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 178.3 mmHg 13.0 22.52 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65695 613
WKY.SHRSP-(D2Mit5-D2Mgh12)/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 163.0 mmHg 3.8 6.58 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65699 613
WKY.SHRSP-(D2Mit5-D2Mgh12)/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 105.4 mmHg 6.3 10.91 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65705 613
WKY.SHRSP-(D2Mit5-D2Mgh12)/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 120.0 mmHg 6.6 11.43 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65709 613
WKY.SHRSP-(Fst-Pklr)/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 130.6 mmHg 8.2 14.2 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65713 613
SS.SR-(D13Mit9-D13Mit1)/Jr diastolic blood pressure controlled sodium content diet (8 %) (between 62 and 69 days) then controlled exposure to darkness St. Lezin EM, et al., J Clin Invest 1996 Jan 15;97(2):522-7 arterial blood pressure trait female 56.0 days-63.0 days 8 serial mean 89.0 mmHg 1.0 2.83 intra-aortic abdominal radiotelemetry 604800.0 5 s every 5 min nightly for a week 11709 119
WKY/NCrl systolic blood pressure controlled exposure to darkness (for 12 hours) Iwai N, et al., Circulation 1999 Nov 2;100(18):1923-9. arterial blood pressure trait male 112.0 days 7 130.0 mmHg 0.57 1.5 vascular indwelling catheter method left common carotid artery 0.0 nighttime (7 PM - 7 AM) 70082 1281
BN/NHsdMcwi systolic blood pressure controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days) then controlled exposure to darkness (for 12 hours) Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. arterial blood pressure trait female 89.0 days-91.0 days 20 serial mean 130.0 mmHg 3.5 15.65 vascular indwelling catheter method left femoral artery 0.0 69443 151
SS/JrHsdMcwi mean arterial blood pressure controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days) then controlled exposure to darkness (for 12 hours) Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. arterial blood pressure trait female 89.0 days-91.0 days 15 serial mean 159.0 mmHg 6.0 23.24 vascular indwelling catheter method left femoral artery 0.0 69448 151
SS/JrHsdMcwi heart rate controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days) then controlled exposure to darkness (for 12 hours) Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. heart pumping trait female 89.0 days-91.0 days 15 serial mean 442.0 beats/min 6.5 25.17 vascular indwelling catheter method left femoral artery 0.0 69450 151
WKY.SHR-(D1Mgh14-D1Rat77)/Iwai diastolic blood pressure controlled sodium content diet (8 %) (for 14 days) then controlled exposure to darkness (for 12 hours) Iwai N, et al., Circulation 1999 Nov 2;100(18):1923-9. arterial blood pressure trait male 126.0 days 8 96.8 mmHg 0.88 2.5 vascular indwelling catheter method left common carotid artery 0.0 nighttime (7 PM - 7 AM) 70096 1281
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 87.0 days 5 110.0 uV 14.0 31.3 electroretinography cornea 0.0 plasmid delivery 71 days scotopic b-wave ERG 108736 3131
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 48.0 days 5 17.0 uV 18.0 40.25 electroretinography cornea 0.0 subretinal injection 28 days adenovirus a-wave amplitude ERG 108381 3121
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 51.68 uV 12.61 30.89 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108404 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 327.83 uV 16.41 40.2 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108405 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 430.17 uV 45.59 111.67 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108409 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 62.22 uV 18.42 45.12 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108410 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 638.33 uV 68.2 167.06 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108414 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 95.25 uV 7.15 17.51 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108418 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 202.5 uV 12.47 30.55 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108420 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 65.42 uV 13.87 33.97 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108428 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 42.97 uV 8.99 22.02 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108434 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 497.33 uV 42.65 104.47 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108437 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 570.67 uV 21.08 51.64 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108438 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 8.38 uV 1.81 4.43 electroretinography cornea 0.0 subretinal injection 30 min pbs a-wave amplitude ERG 108446 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 516.5 uV 29.8 72.99 electroretinography cornea 0.0 subretinal injection 30 min pbs b-wave amplitude ERG 108461 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 5.17 uV 1.18 3.91 electroretinography cornea 0.0 subretinal injection 2 days CHPG a-wave amplitude ERG 108464 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 18.46 uV 3.3 10.94 electroretinography cornea 0.0 subretinal injection 2 days pbs a-wave amplitude ERG 108471 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 607.73 uV 58.9 195.35 electroretinography cornea 0.0 subretinal injection 2 days pbs b wave amplitude ERG 108487 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 30.66 uV 9.93 24.32 electroretinography cornea 0.0 subretinal injection 10 days pbs a wave amplitude ERG 108495 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 178.0 uV 12.3 30.13 electroretinography cornea 0.0 subretinal injection 10 days pbs a wave amplitude ERG 108498 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 485.67 uV 73.15 179.18 electroretinography cornea 0.0 subretinal injection 10 days CHPG b-wave amplitude ERG 108503 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 511.83 uV 65.06 159.36 electroretinography cornea 0.0 subretinal injection 10 days CHPG b-wave amplitude ERG 108504 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 101.1 uV 20.75 50.83 electroretinography cornea 0.0 subretinal injection 10 days pbs b wave amplitude ERG 108506 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 208.5 uV 14.36 35.17 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP a-wave amplitude ERG 108516 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 16.61 uV 4.28 10.48 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs a-wave amplitude ERG 108518 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 800.0 uV 67.71 165.85 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP b-wave amplitude ERG 108529 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 423.33 uV 25.5 62.46 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs b-wave amplitude ERG 108534 3123
Hsd:SD scotopic B wave amplitude of ERG waveform gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 9 397.0 uV electroretinography cornea 0.0 subretinal injection 30 days scotopic b-wave ERG 108652 3128
Hsd:SD scotopic A wave amplitude of ERG waveform gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 9 173.0 uV electroretinography cornea 0.0 subretinal injection 30 days scotopic a-wave ERG 108654 3128
RCS/LavRrrc b-wave amplitude of ERG waveform gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (40 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (2.5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. eye electrophysiology trait both  days 5 137.0 uV 18.0 40.25 electroretinography cornea 0.0 subretinal injection 60 days scotopic b-wave ERG 108664 3128
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 75.0 days 5 29.7 uV 11.3 25.27 electroretinography cornea 0.0 plasmid delivery 59 days pVAX2-rGDNF scotopic a-wave ERG 108729 3131
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 70.0 days 3 20.9 uV 3.7 6.41 electroretinography cornea 0.0 plasmid delivery 54 days pVAX2-rGDNF scotopic a-wave ERG 108748 3131
Hsd:SD scotopic A wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 4 202.0 uV electroretinography cornea 0.0 scotopic a-wave ERG 108643 3128
Hsd:SD scotopic A wave amplitude of ERG waveform gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 9 154.0 uV electroretinography cornea 0.0 subretinal injection 30 days scotopic a-wave ERG 108648 3128
Hsd:SD scotopic A wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 9 195.0 uV electroretinography cornea 0.0 scotopic a-wave ERG 108649 3128
Hsd:SD scotopic B wave amplitude of ERG waveform gene transfer of the rat MER proto-oncogene, tyrosine kinase gene using an adenovirus vector (4 x 10E8 vg) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 9 387.0 uV electroretinography cornea 0.0 subretinal injection 30 days scotopic b-wave ERG 108646 3128
RCS/LavRrrc scotopic B wave amplitude of ERG waveform human periodontal ligament-derived stem cells (0.2 x 10E6 cells) then controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 35.0 days 4 143.41 uV 12.18 24.35 electroretinography retina 0.0 hPDLSC transplant 14 days 109854 3157
RCS/N scotopic A wave amplitude of ERG waveform lensotomy then controlled exposure to darkness (for 1 days) then visible light stimulus (100 cd x s/m2) Heiduschka P, et al., ISRN Ophthalmol. 2013 Sep 19;2013:814814. doi: 10.1155/2013/814814. eCollection 2013. rod electrophysiology trait not specified 60.0 days 3 18.3 uV 4.79 8.3 electroretinography cornea 0.0 lens puncture 30 days scotopic a-wave ERG 108566 3124
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 53.0 days 5 352.0 uV 26.0 58.14 electroretinography cornea 0.0 plasmid delivery 37 days scotopic b-wave ERG 108728 3131
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform sham gene transfer using an empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 75.0 days 5 114.0 uV 16.0 35.78 electroretinography cornea 0.0 plasmid delivery 59 days scotopic b-wave ERG 108732 3131
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 172.6 uV 20.12 49.28 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP a-wave amplitude ERG 108515 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 33.73 uV 9.28 24.55 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108540 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 233.29 uV 18.61 49.24 electroretinography cornea 0.0 subretinal injection 4 days pbs a wave amplitude ERG 108546 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 192.0 uV 14.42 38.15 electroretinography cornea 0.0 subretinal injection 4 days pbs a wave amplitude ERG 108545 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 31.22 uV 8.16 21.59 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108551 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 131.7 uV 16.13 42.68 electroretinography cornea 0.0 subretinal injection 4 days pbs b-wave amplitude ERG 108557 3123
SHRSP/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 229.8 mmHg 7.3 12.64 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65651 613
SHRSP/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 151.6 mmHg 3.9 6.75 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65661 613
SHRSP.WKY-(D2Rat13-D2Mit5)/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait female 126.0 days-147.0 days 3 continuous mean 144.2 mmHg 4.5 7.79 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65697 613
WKY.SHRSP-(D2Mit5-D2Mgh12)/Gcrc diastolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 118.2 mmHg 5.6 9.7 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65703 613
WKY.SHRSP-(D2Mit5-D2Mgh12)/Gcrc mean arterial blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 133.1 mmHg 4.8 8.31 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65707 613
WKY.SHRSP-(Fst-Pklr)/Gcrc systolic blood pressure controlled sodium content drinking water (1 %) (for 21 days) and controlled exposure to darkness Jeffs B, et al., Hypertension 2000 Jan;35(1 Pt 2):179-87. arterial blood pressure trait male 126.0 days-147.0 days 3 continuous mean 156.0 mmHg 2.5 4.33 intra-aortic abdominal radiotelemetry 1814400 Nights (7 PM to 7 AM) 65711 613
SS/JrHsdMcwi absolute change in mean arterial blood pressure controlled sodium content diet (0.4 %) (for 28 days) then controlled sodium content diet (8 %) (for 30 days) then controlled exposure to ambient light (for 12 hours) then controlled exposure to darkness (for 12 hours) Cowley AW Jr, et al., Physiol Genomics 2000 Apr 27;2(3):107-15. arterial blood pressure trait male 91.0 days-93.0 days 35 continuous mean 7.0 mmHg 7.0 41.41 vascular indwelling catheter method femoral artery 0.0 left femoral artery decrease 64931 229
SS.SR-(D13Mit9-D13Mit1)/Jr systolic blood pressure controlled sodium content diet (8 %) (between 62 and 69 days) then controlled exposure to darkness St. Lezin EM, et al., J Clin Invest 1996 Jan 15;97(2):522-7 arterial blood pressure trait female 56.0 days-63.0 days 8 serial mean 122.0 mmHg 2.0 5.66 intra-aortic abdominal radiotelemetry 604800.0 5 s every 5 min nightly for a week 11707 119
SR/Jr systolic blood pressure controlled sodium content diet (8 %) (between 48 and 55 days) then controlled exposure to darkness St. Lezin EM, et al., J Clin Invest 1996 Jan 15;97(2):522-7 arterial blood pressure trait male 70.0 days-77.0 days 7 serial mean 144.0 mmHg 4.0 10.58 intra-aortic abdominal radiotelemetry 604800.0 5 s every 5 min nightly for a week 11695 119
BN/NHsdMcwi mean arterial blood pressure controlled sodium content diet (0.1 %) (for 28 days) then controlled sodium content diet (8 %) (for 30 days) and controlled exposure to darkness (for 12 hours) Cowley AW Jr, et al., Physiol Genomics 2000 Apr 27;2(3):107-15. arterial blood pressure trait male 91.0 days-93.0 days 42 continuous mean 114.0 mmHg 4.0 25.92 vascular indwelling catheter method femoral artery 14400.0 left femoral artery 12016 229
BN/NHsdMcwi diastolic blood pressure controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days) then controlled exposure to darkness (for 12 hours) Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57. arterial blood pressure trait female 89.0 days-91.0 days 20 serial mean 96.0 mmHg 2.7 12.07 vascular indwelling catheter method left femoral artery 0.0 69445 151
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. rod electrophysiology trait both 87.0 days 5 17.1 uV 3.2 7.16 electroretinography cornea 0.0 plasmid delivery 71 days pVAX2-rGDNF scotopic a-wave ERG 108733 3131
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 34.0 days 8 20.0 uV 20.0 56.57 electroretinography cornea 0.0 subretinal injection 14 days adenovirus a-wave amplitude ERG 108375 3121
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 62.0 days 5 8.9 uV 9.9 22.14 electroretinography 0.0 untreated control a-wave amplitude ERG 108386 3121
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 62.0 days 5 14.0 uV 17.0 38.01 electroretinography cornea 0.0 subretinal injection 42 days adenovirus b-wave amplitude ERG 108390 3121
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 62.0 days 5 34.0 uV 27.0 60.37 electroretinography cornea 0.0 subretinal injection 42 days adenovirus b-wave amplitude ERG 108391 3121
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 8.81 uV 1.84 4.51 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108392 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 78.43 uV 13.51 33.09 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108394 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 118.43 uV 17.52 42.92 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108396 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 224.32 uV 34.64 84.85 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa a-wave amplitude ERG 108403 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 391.5 uV 33.43 81.89 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108407 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 532.5 uV 62.77 153.75 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108412 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 652.5 uV 65.65 160.81 electroretinography cornea 0.0 subretinal injection 7 days dl-aaa b-wave amplitude ERG 108415 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 23.02 uV 5.24 12.84 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108417 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 94.57 uV 13.87 33.97 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108424 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 27.7 uV 4.72 11.56 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108423 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 243.17 uV 24.11 59.06 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa a-wave amplitude ERG 108427 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 382.17 uV 30.52 74.76 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108430 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 519.33 uV 29.94 73.34 electroretinography cornea 0.0 subretinal injection 10 days dl-aaa b-wave amplitude ERG 108432 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 88.5 uV 12.52 30.67 electroretinography cornea 0.0 subretinal injection 30 min CHPG a-wave amplitude ERG 108442 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 25.21 uV 4.23 10.36 electroretinography cornea 0.0 subretinal injection 30 min CHPG a-wave amplitude ERG 108441 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 155.28 uV 13.68 33.51 electroretinography cornea 0.0 subretinal injection 30 min CHPG a-wave amplitude ERG 108443 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 216.67 uV 19.46 47.67 electroretinography cornea 0.0 subretinal injection 30 min CHPG a-wave amplitude ERG 108445 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 56.16 uV 17.2 42.13 electroretinography cornea 0.0 subretinal injection 30 min CHPG b-wave amplitude ERG 108452 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 381.17 uV 37.99 93.06 electroretinography cornea 0.0 subretinal injection 30 min CHPG b-wave amplitude ERG 108453 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 584.5 uV 38.15 93.45 electroretinography cornea 0.0 subretinal injection 30 min pbs b-wave amplitude ERG 108462 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 11.68 uV 2.42 8.03 electroretinography cornea 0.0 subretinal injection 2 days CHPG a-wave amplitude ERG 108465 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 137.5 uV 12.91 42.82 electroretinography cornea 0.0 subretinal injection 2 days CHPG a-wave amplitude ERG 108469 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 270.09 uV 34.35 113.93 electroretinography cornea 0.0 subretinal injection 2 days CHPG b-wave amplitude ERG 108477 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 466.45 uV 51.69 171.44 electroretinography cornea 0.0 subretinal injection 2 days pbs b wave amplitude ERG 108484 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 518.55 uV 54.69 181.39 electroretinography cornea 0.0 subretinal injection 2 days pbs b wave amplitude ERG 108485 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 11 567.73 uV 56.78 188.32 electroretinography cornea 0.0 subretinal injection 2 days pbs b wave amplitude ERG 108486 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 15.46 uV 4.1 10.04 electroretinography cornea 0.0 subretinal injection 10 days CHPG a-wave amplitude ERG 108488 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 80.6 uV 11.3 27.68 electroretinography cornea 0.0 subretinal injection 10 days CHPG a-wave amplitude ERG 108490 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 71.98 uV 18.54 45.41 electroretinography cornea 0.0 subretinal injection 10 days CHPG b-wave amplitude ERG 108500 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 385.17 uV 61.99 151.84 electroretinography cornea 0.0 subretinal injection 10 days CHPG b-wave amplitude ERG 108501 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 625.0 uV 55.4 135.7 electroretinography cornea 0.0 subretinal injection 10 days pbs b wave amplitude ERG 108511 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 57.63 uV 8.8 21.56 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs a-wave amplitude ERG 108520 3123
RCS-rdy+ p+/LavRrrc scotopic A wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 124.83 uV 7.26 17.78 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + pbs a-wave amplitude ERG 108522 3123
RCS-rdy+ p+/LavRrrc scotopic B wave amplitude of ERG waveform DL-α-aminoadipate (70 ug/ul) and 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both  days 6 739.67 uV 44.42 108.81 electroretinography cornea 0.0 subretinal injection 2 days dl-aaa + MPEP b-wave amplitude ERG 108527 3123
Hsd:SD scotopic B wave amplitude of ERG waveform vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 4 338.0 uV electroretinography cornea 0.0 subretinal injection 30 days scotopic b-wave ERG 108640 3128
Hsd:SD scotopic A wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 9 203.0 uV electroretinography cornea 0.0 scotopic a-wave ERG 108655 3128
Hsd:SD scotopic B wave amplitude of ERG waveform controlled exposure to darkness (for 12 hours) then visible light stimulus (5 cd/m2) Conlon TJ, et al., Hum Gene Ther Clin Dev. 2013 Mar;24(1):23-8. doi: 10.1089/humc.2013.037. Epub 2013 Apr 3. rod electrophysiology trait both  days 9 491.0 uV electroretinography cornea 0.0 scotopic b-wave ERG 108653 3128
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 34.0 days 8 34.0 uV 26.0 73.54 electroretinography cornea 0.0 subretinal injection 14 days adenovirus a-wave amplitude ERG 108376 3121
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform control condition then controlled exposure to darkness (for 12 hours) Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. rod electrophysiology trait both 48.0 days 5 48.0 uV 26.0 58.14 electroretinography 0.0 untreated control b-wave amplitude ERG 108383 3121
RCS/LavRrrc scotopic B wave amplitude of ERG waveform vehicle control condition (2 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus Huang L, et al., Stem Cell Res Ther. 2017 Dec 22;8(1):290. doi: 10.1186/s13287-017-0731-y. rod electrophysiology trait not specified 77.0 days 4 13.01 uV 1.85 3.69 electroretinography retina 0.0 pbs vehicle injection 56 days 109862 3157
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 36.49 uV 10.37 27.44 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108541 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 83.4 uV 14.8 39.16 electroretinography cornea 0.0 subretinal injection 4 days pbs a wave amplitude ERG 108543 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 7.44 uV 1.43 3.78 electroretinography cornea 0.0 subretinal injection 4 days pbs a wave amplitude ERG 108542 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 15.31 uV 2.98 7.88 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108549 3123
RCS-p+/LavRrrc scotopic B wave amplitude of ERG waveform 2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 251.29 uV 19.14 50.64 electroretinography cornea 0.0 subretinal injection 4 days pbs a wave amplitude ERG 108547 3123
RCS-p+/LavRrrc scotopic A wave amplitude of ERG waveform phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. rod electrophysiology trait both 39.0 days 7 24.79 uV 7.82 20.69 electroretinography cornea 0.0 subretinal injection 4 days MPEP a-wave amplitude ERG 108552 3123